CA3252338A1 - SYNTHESIS OF BRUTON TYROSINE KINASE INHIBITORS - Google Patents
SYNTHESIS OF BRUTON TYROSINE KINASE INHIBITORSInfo
- Publication number
- CA3252338A1 CA3252338A1 CA3252338A CA3252338A CA3252338A1 CA 3252338 A1 CA3252338 A1 CA 3252338A1 CA 3252338 A CA3252338 A CA 3252338A CA 3252338 A CA3252338 A CA 3252338A CA 3252338 A1 CA3252338 A1 CA 3252338A1
- Authority
- CA
- Canada
- Prior art keywords
- bruton
- synthesis
- tyrosine kinase
- kinase inhibitors
- inhibitors
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/24—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Health & Medical Sciences (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Pyridine Compounds (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GR20220100151 | 2022-02-18 | ||
| GR20220100151 | 2022-02-18 | ||
| EP22167032 | 2022-04-06 | ||
| EP22167032.6 | 2022-04-06 | ||
| EP22178413.5 | 2022-06-10 | ||
| EP22178413 | 2022-06-10 | ||
| PCT/EP2023/054043 WO2023156599A1 (en) | 2022-02-18 | 2023-02-17 | Synthesis of bruton's tyrosine kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3252338A1 true CA3252338A1 (en) | 2023-08-24 |
Family
ID=85227338
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3252338A Pending CA3252338A1 (en) | 2022-02-18 | 2023-02-17 | SYNTHESIS OF BRUTON TYROSINE KINASE INHIBITORS |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20250163076A1 (https=) |
| EP (1) | EP4479405A1 (https=) |
| JP (1) | JP2025506671A (https=) |
| KR (1) | KR20240148351A (https=) |
| AU (1) | AU2023221549A1 (https=) |
| CA (1) | CA3252338A1 (https=) |
| CL (1) | CL2024002409A1 (https=) |
| CO (1) | CO2024011229A2 (https=) |
| IL (1) | IL314902A (https=) |
| JO (1) | JOP20240182A1 (https=) |
| MX (1) | MX2024010134A (https=) |
| PE (1) | PE20242069A1 (https=) |
| WO (1) | WO2023156599A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025262118A1 (en) * | 2024-06-20 | 2025-12-26 | Janssen Pharmaceutica Nv | Combination therapy using a malt1 inhibitor and a btk inhibitor |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3794B1 (ar) * | 2015-12-10 | 2021-01-31 | Janssen Pharmaceutica Nv | المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون |
| WO2018103060A1 (en) * | 2016-12-09 | 2018-06-14 | Janssen Pharmaceutica Nv | Inhibitors of bruton's tyrosine kinase and methods of their use |
-
2023
- 2023-02-17 AU AU2023221549A patent/AU2023221549A1/en active Pending
- 2023-02-17 KR KR1020247027226A patent/KR20240148351A/ko active Pending
- 2023-02-17 EP EP23705025.7A patent/EP4479405A1/en active Pending
- 2023-02-17 WO PCT/EP2023/054043 patent/WO2023156599A1/en not_active Ceased
- 2023-02-17 MX MX2024010134A patent/MX2024010134A/es unknown
- 2023-02-17 JP JP2024547937A patent/JP2025506671A/ja active Pending
- 2023-02-17 IL IL314902A patent/IL314902A/en unknown
- 2023-02-17 PE PE2024001734A patent/PE20242069A1/es unknown
- 2023-02-17 US US18/838,678 patent/US20250163076A1/en active Pending
- 2023-02-17 CA CA3252338A patent/CA3252338A1/en active Pending
-
2024
- 2024-08-12 CL CL2024002409A patent/CL2024002409A1/es unknown
- 2024-08-14 JO JOJO/P/2024/0182A patent/JOP20240182A1/ar unknown
- 2024-08-20 CO CONC2024/0011229A patent/CO2024011229A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2024010134A (es) | 2024-08-27 |
| KR20240148351A (ko) | 2024-10-11 |
| EP4479405A1 (en) | 2024-12-25 |
| IL314902A (en) | 2024-10-01 |
| PE20242069A1 (es) | 2024-10-18 |
| JP2025506671A (ja) | 2025-03-13 |
| JOP20240182A1 (ar) | 2024-08-14 |
| CO2024011229A2 (es) | 2024-08-30 |
| US20250163076A1 (en) | 2025-05-22 |
| WO2023156599A1 (en) | 2023-08-24 |
| AU2023221549A1 (en) | 2024-10-03 |
| CL2024002409A1 (es) | 2025-01-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL308219A (en) | Compounds to Target Broton Tyrosine Kinase Degradation | |
| WO2004031401A3 (en) | Novel tyrosine kinases inhibitors | |
| YU84603A (sh) | Novi inhibitori tirozin kinaze | |
| MA30952B1 (fr) | Cyclopenta [d] pyrimidines utiles en tant qu'inhibiteurs de la proteine kinase akt | |
| WO2004063151A3 (en) | Novel tyrosine kinase inhibitors | |
| BRPI0412894A (pt) | tienopiridina e furopiridina inibidores de quinases | |
| WO2004014300A3 (en) | Tyrosine kinase inhibitors | |
| IL308951A (en) | Inhibitors of proton tyrosine kinase and methods of using them | |
| ATE482938T1 (de) | Tyrosinkinaseinhibitoren | |
| AU2003250701A1 (en) | Protein tyrosine kinase inhibitors | |
| WO2002081728A3 (en) | Quinoline inhibitors of hyak1 and hyak3 kinases | |
| CA3252338A1 (en) | SYNTHESIS OF BRUTON TYROSINE KINASE INHIBITORS | |
| EP4138842A4 (en) | METHODS OF USING RHO-KINASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | |
| WO2024216017A3 (en) | Synthesis of ras inhibitors | |
| NZ779146A (en) | Cyclic molecules as bruton’s tyrosine kinase inhibitor | |
| WO2003035619A8 (en) | Tyrosine kinase inhibitors | |
| IL314260A (en) | Pyrimidines for Broton's tyrosine kinase degradation | |
| HK40107548A (en) | Compounds for targeting degradation of bruton's tyrosine kinase | |
| DE60316423D1 (de) | Tyrosinkinase-hemmer | |
| HK40108993A (en) | Inhibitors of bruton's tyrosine kinase and methods of their use | |
| EP4069689A4 (en) | SUBSTITUTED IMIDAZOLECARBOXAMIDE AS BRUTON TYROSINKINASE INHIBITORS | |
| WO2020232330A8 (en) | Inhibiting agents for bruton's tyrosine kinase | |
| ATE396727T1 (de) | Tyrosinkinase-hemmer | |
| CA3292426A1 (en) | Methods of treating relapsing multiple sclerosis using an inhibitor of bruton's tyrosine kinase | |
| HK40118285A (zh) | Cdk4/6激酶的抑制剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT Effective date: 20240815 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20240815 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250204 |
|
| A15 | Pct application entered into the national or regional phase |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250507 |
|
| P18 | Priority claim added or amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250507 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250507 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250509 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250509 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250509 |
|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET Effective date: 20250512 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST TO REGISTER A DOCUMENT RECEIVED Effective date: 20250527 Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250527 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250808 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250819 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260105 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260105 |